Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mono PharmacareNSE:MONOPHARMA +3.29%9 PB Ratio is 0.52 as of Aug. 12, 2026, which is 68% below its 10-year median of 1.60. GuruFocus rates NSE:MONOPHARMA with a GF Score™ of 9/100. The stock has 6 warning signs investors should review. Among 610 Healthcare Providers & Services companies, Mono Pharmacare ranks better than 92.46% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-12), Mono Pharmacare's share price is ₹7.85. Mono Pharmacare's Book Value per Share for the quarter that ended in Sep. 2025 was ₹15.23. Hence, Mono Pharmacare's PB Ratio of today is 0.52.
The historical rank and industry rank for Mono Pharmacare's PB Ratio or its related term are showing as below:
NSE:MONOPHARMA'
s PB Ratio Range Over the Past 10 Years
Min: 0.44 Med: 1.6 Max: 9.37
Current: 0.52
During the past 5 years, Mono Pharmacare's highest PB Ratio was 9.37. The lowest was 0.44. And the median was 1.60.
NSE:MONOPHARMA's PB Ratio is ranked better than 92.46% of 610
companies
in the Healthcare Providers & Services industry
Industry Median: 2.065
vs NSE:MONOPHARMA: 0.52
During the past 12 months, Mono Pharmacare's average Book Value Per Share Growth Rate was -11.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 94.00% per year.
During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Mono Pharmacare was 96.60% per year. The lowest was 94.00% per year. And the median was 95.30% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Mono Pharmacare PB Ratio Related Terms
Mono Pharmacare PB Ratio Historical Data
* Premium members only.
The historical data trend for Mono Pharmacare's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Mono Pharmacare's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mono Pharmacare PB Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Mono Pharmacare's PB Ratio distribution charts can be found below:
* The bar in red indicates where Mono Pharmacare's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Mono Pharmacare's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Mono Pharmacare (NSE:MONOPHARMA) has a PB Ratio of 0.52 as of Aug. 12, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Mono Pharmacare and its competitors. This is 68% below median its historical median of 1.60. Over the past decade, Mono Pharmacare's PB Ratio has ranged from 0.44 to 9.37. According to the industry distribution chart, Mono Pharmacare ranks #46 out of 610 companies in the Healthcare Providers & Services industry, placing it in the top 7.5%.
Is Mono Pharmacare's PB Ratio too high?
Mono Pharmacare's current PB Ratio of 0.52 is 68% below median its 10-year median of 1.60. Over the past 10 years, this metric has ranged from a low of 0.44 to a high of 9.37. The Healthcare Providers & Services industry median PB Ratio is 2.07. Mono Pharmacare's value of 0.52 is 74.8% below this industry median. Based on the distribution chart, Mono Pharmacare ranks #46 out of 610 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Mono Pharmacare has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Mono Pharmacare's PB Ratio compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Mono Pharmacare ranks #46 out of 610 companies for PB Ratio. This places Mono Pharmacare in the top 8% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.07. Mono Pharmacare's value of 0.52 is 74.8% below this benchmark. Historically, Mono Pharmacare's own PB Ratio has ranged from 0.44 to 9.37 over the past decade. While the company's 10-year median is 1.60 vs. the industry median of 2.07, Mono Pharmacare has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Healthcare Providers & Services company?
The median PB Ratio among Healthcare Providers & Services companies is 2.07, based on 610 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mono Pharmacare's current PB Ratio of 0.52 is 74.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Mono Pharmacare and its competitors. For the Healthcare Providers & Services industry, the median PB Ratio is 2.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mono Pharmacare's current PB Ratio is 0.52, which is 68% below median its own 10-year median of 1.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mono Pharmacare stock overvalued right now?
Mono Pharmacare (NSE:MONOPHARMA) has a current PB Ratio of 0.52. The current PB Ratio is 0.52, which is 68% below median its 10-year median of 1.60 and 74.8% below the Healthcare Providers & Services industry median of 2.07. Mono Pharmacare's overall GF Score™ is 9/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Mono Pharmacare (NSE:MONOPHARMA), the current PB Ratio is 0.52 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mono Pharmacare Ltd distributes a broad range of pharmaceutical products across India. Its portfolio includes antibiotics, antifungal medicines, cough and cold remedies, antacids, analgesics, nutraceuticals, skincare, antiseptics, cardiac and diabetic drugs, and cosmetic items. The company operates through contract manufacturing, sourcing products from various manufacturers and supplying them to healthcare providers and pharmacies. Revenue is generated through the sales and distribution of these pharmaceutical and healthcare products in the Indian market.
9GF Score
Get the complete analysis for NSE:MONOPHARMA
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MONOPHARMA has been successfully added to your 
